Compare BWEN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.5M | 111.1M |
| IPO Year | 2009 | 2020 |
| Metric | BWEN | FHTX |
|---|---|---|
| Price | $2.93 | $2.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $6.83 | $4.17 |
| AVG Volume (30 Days) | 177.8K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 360.00 | 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,785,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.92 | $1.79 |
| 52 Week High | $5.70 | $7.61 |
| Indicator | BWEN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.27 | 24.78 |
| Support Level | $1.98 | $1.79 |
| Resistance Level | $3.35 | $5.27 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 0.00 | 58.57 |
Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.